Eastman Chemical Company (EMN)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-10-30
$66.53-2.06%
Close 2026-10-30 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-10-30
Research Workspace
Put EMN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Positive cash flow from operations: Cash from operations: $224M.
View ThesisRevenue is growing steadily — about 0% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskEastman’s circular platform depends on expanding Kingsport methanolysis as revenue growth slows from 10% to 8%. Third-quarter 2026 revenue grew 8% year over year, while adjusted earnings missed consensus. The shares trade at 13× P/E versus the 17× peer median. Expectations look modest versus our view, though the premium depends on maintaining cash generation. Our model puts the next-quarter miss probability near 36%. Peer multiples imply a price about 23% above where it trades; the thesis is on watch.
Trailing returns as of 2026-10-30. EMN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering EMN (as of Oct 2026).
Based on 8 Wall Street analysts offering 12-month price targets for EMN in the last 4 months.
Continue this research
Compare EMN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EMN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put EMN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Grow the circular platform through Kingsport methanolysis
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $66.53
The last 12 months of price, then the range of analyst 12-month targets from today’s $66.53.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
DOE support and expansion advance Kingsport methanolysis; stated 2027 capex baseline is above the 2026 objective.
Advances: Drive growth through innovation and Kingsport methanolysis facility
New product selection supports growth through innovation.
Advances: Reduce costs by $125M to $150M net of inflation
Cost reduction and capacity increase align with management's goals.
Advances: Enhance cash flow from operations
Price target hikes indicate confidence in cash flow enhancement.
Threatens: Focus on cost reduction initiatives
Earnings miss may hinder cost reduction initiatives.
Threatens: Enhance cash flow from operations
Expected profit dip could impact cash flow from operations.
